CANGRELOR Drug Interactions: What You Need to Know

INTERACTIONS Clopidogrel: Do not administer during KENGREAL infusion. ( 7.1 ) Prasugrel: Do not administer during KENGREAL infusion. ( 7.1 )

7.1 Thienopyridines Clopidogrel or prasugrel administered during KENGREAL infusion will have no antiplatelet effect until the next dose is administered. Therefore, administer clopidogrel or prasugrel after KENGREAL infusion is discontinued <span class="opacity-50 text-xs">[see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )]</span>.

7.1 Thienopyridines Clopidogrel or prasugrel administered during KENGREAL infusion will have no antiplatelet effect until the next dose is administered. Therefore, administer clopidogrel or prasugrel after KENGREAL infusion is discontinued <span class="opacity-50 text-xs">[see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )]</span>.

Significant active bleeding ( 4.1 ) Hypersensitivity to KENGREAL or any component of the product ( 4.2 )

4.1 Significant Active Bleeding KENGREAL is contraindicated in patients with significant active bleeding <span class="opacity-50 text-xs">[see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )]</span> .

4.2 Hypersensitivity KENGREAL is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to KENGREAL or any component of the product <span class="opacity-50 text-xs">[see Adverse Reactions ( 6.1 )]</span> .

4.1 Significant Active Bleeding KENGREAL is contraindicated in patients with significant active bleeding <span class="opacity-50 text-xs">[see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )]</span> .

4.2 Hypersensitivity KENGREAL is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to KENGREAL or any component of the product <span class="opacity-50 text-xs">[see Adverse Reactions ( 6.1 )]</span> .

AND PRECAUTIONS Bleeding: Like other drugs that inhibit platelet P2Y 12 function, KENGREAL can increase the risk of bleeding ( 5.1 )

5.1 Bleeding Drugs that inhibit platelet P2Y 12 function, including KENGREAL, increase the risk of bleeding. In CHAMPION PHOENIX bleeding events of all severities were more common with KENGREAL than with clopidogrel <span class="opacity-50 text-xs">[see Adverse Reactions ( 6.1 )]</span> . Bleeding complications with KENGREAL were consistent across a variety of clinically important subgroups (see Figure 1). Once KENGREAL is discontinued, there is no antiplatelet effect after an hour <span class="opacity-50 text-xs">[see Clinical Pharmacology ( 12.3 )]</span> .

5.1 Bleeding Drugs that inhibit platelet P2Y 12 function, including KENGREAL, increase the risk of bleeding. In CHAMPION PHOENIX bleeding events of all severities were more common with KENGREAL than with clopidogrel <span class="opacity-50 text-xs">[see Adverse Reactions ( 6.1 )]</span> . Bleeding complications with KENGREAL were consistent across a variety of clinically important subgroups (see Figure 1). Once KENGREAL is discontinued, there is no antiplatelet effect after an hour <span class="opacity-50 text-xs">[see Clinical Pharmacology ( 12.3 )]</span> .